ArticleMethods in molecular biology (Clifton, N.J.)2022
A Quantum Vaccinomics Approach Based on Protein-Protein Interactions.
Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Modelling protein-protein interactions for the design of vaccine chimeric antigens with protective epitopes.PloS one · 2025Article
- Artificial intelligence-, organoid-, and organ-on-chip-powered models to improve pre-clinical animal testing of vaccines and immunotherapeutics: potential, progress, and challenges.Frontiers in artificial intelligence · 2025Review
- Interventions for the control of Crimean-Congo hemorrhagic fever and tick vectors.NPJ vaccines · 2024Review
- Evolution of tick vaccinology.Parasitology · 2024Review
- The Role of Biophysical Factors in Organ Development: Insights from Current Organoid Models.Bioengineering (Basel, Switzerland) · 2024Review
- Quantum vaccinomics platforms to advance in vaccinology.Frontiers in immunology · 2023Article
- A Quantum Vaccinomics Approach for the Design and Production of MSP4 Chimeric Antigen for the Control ofVaccines · 2022Article
- One Health Approach to Identify Research Needs onPathogens (Basel, Switzerland) · 2022Article
- Differentially Represented Proteins in Response to Infection withPathogens (Basel, Switzerland) · 2022Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccines are the most effective preventive intervention to reduce the impact of infectious diseases worldwide. In particular, tick-borne diseases represent a growing burden for human and animal health worldwide and vaccines are the most effective and environmentally sound approach for the control of vector infestations and pathogen transmission. However, the development of effective vaccines for the control of tick-borne diseases with combined vector-derived and pathogen-derived antigens is one of the limitations for the development of effective vaccine formulations. Quantum biology arise from findings suggesting that living cells operate under non-trivial features of quantum mechanics, which has been proposed to be involved in DNA mutation biological process. Then, the electronic structure of the molecular interactions behind peptide immunogenicity led to quantum immunology and based on the definition of the photon as a quantum of light, the immune protective epitopes were proposed as the immunological quantum. Recently, a quantum vaccinomics approach was proposed based on the characterization of the immunological quantum to further advance the design of more effective and safe vaccines. In this chapter, we describe methods of the quantum vaccinomics approach based on proteins with key functions in cell interactome and regulome of vector-host-pathogen interactions for the identification by yeast two-hybrid screen and the characterization by in vitro protein-protein interactions and musical scores of protein interacting domains, and the characterization of conserved protective epitopes in protein interacting domains. These results can then be used for the design and production of chimeric protective antigens.
Indexed as
Identifiers
34816412What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.